Please provide your email address to receive an email when new articles are posted on . At 52 weeks, MASH resolution without worsening of fibrosis was reported among 36% on denifanstat vs. 13% on ...

Digital pathology assisted by artificial intelligence (AI) has the potential to transform the diagnosis and treatment of fibrotic liver disease in the next few years and to reshape clinical trials, ...

Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

(A) scRNA-seq with ST can reveal spatial zonation profiles of gene expression in the normal liver and a detailed cell landscape of the human liver, showing that 50% of liver genes have partitioning ...

A medication long used to help people breathe may soon help protect the liver as well. Researchers at the Medical University ...

New research shows that Vitamin E therapy significantly enhances liver function and reduces inflammation in MASH patients, providing a safer and effective treatment option in the fight against ...

More than 6 million adults in the United States live with metabolic dysfunction-associated steatohepatitis, or MASH, a severe form of fatty liver disease that can silently progress to cirrhosis, liver ...